Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30216059 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CA1CA2CA9KDM4E | |
| SCHEMBL29683246 | 0.82 | ALDH1A1 (0.44) | ALDH1A1CA1CA2CA9KDM4E | |
| SCHEMBL4310399 | 0.82 | ALDH1A1 (0.44) | ALDH1A1CA1CA2CA9KDM4E | |
| SCHEMBL13715404 | 0.79 | KDM4E (0.50) | ALDH1A1CA1CA2CA9KDM4E | |
| SCHEMBL13043443 | 0.79 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL8558945 | 0.79 | ALDH1A1 (0.47) | ALDH1A1CA1CA2CA9KDM4E | |
| SCHEMBL11015754 | 0.78 | ALDH1A1 (0.46) | ALDH1A1CA1CA2CA9KDM4E | |
| SCHEMBL5725486 | 0.78 | ALDH1A1 (0.46) | ALDH1A1CA1CA2CA9KDM4E | |
| SCHEMBL11443101 | 0.76 | ALDH1A1 (0.47) | ALDH1A1CA1CA2CA9KDM4E | |
| SCHEMBL2648754 | 0.74 | CA1 (0.57) | ALDH1A1CA1CA2CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| CN-115768750-A | GCN2 modulator compounds | 阿莱斯塔治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4107146-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2022-12-28 | — | — | EP | disclosed |
| US-20140058129-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8586782-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-11-19 | — | — | US | disclosed |
| US-8362294-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | MONOVICH LAUREN G (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2046723-B1 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | NOVARTIS AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| CN-101479231-A | Phenylacetic acid derivatives as COX-2 inhibitors | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| EP-2046723-A2 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | Novartis AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008002853-A2 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | ALDH1A1 4260/4885CA1 3553/4885CA2 1341/4885 |
| US-20140058129-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | ALDH1A1 37/4885CA1 1546/4885CA2 760/4885 |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | ALDH1A1 4030/4885CA1 4675/4885CA2 2579/4885 |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | ALDH1A1 37/4885CA1 1546/4885CA2 760/4885 |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, PTGER2 | ALDH1A1 36/4885CA1 1592/4885CA2 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.